Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate
The post Lundbeck to acquire US-based Abide Therapeutics for up to $400m appeared first on Pharmaceutical Business review.
Original Article: Lundbeck to acquire US-based Abide Therapeutics for up to $400m